Nature Medicine
2, 274 - 275 (1996)
doi:10.1038/nm0396-274
Closing in on human immunodeficiency virus−1John W. MellorsUniversity of Pittsburgh Medical Center and Department of Veterans Affairs Medical Center Pittsburgh, Pennsylvania 15213, USA Antiretroviral therapy back on track with HIV-1 protease inhibitors.
REFERENCES
- Aboulker, J.P. & Swart, A.M. Preliminary analysis of the Concorde trial. Lancet 329, 889−890 (1993). | Article |
- Fischl, M.A. et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122, 24−32 (1995). | PubMed | ISI | ChemPort |
- Delfraissy, J.F. et al. Abstracts of the IXth Int. Conference on AIDS, Berlin, Germany, p.69 (1993).
- Danner, S.A. et al. Abstracts of the IXth Int. Conference on AIDS, Berlin, Germany, p.69 (1993).
- Chow, Y.K. et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650−654 (1993). | Article | PubMed | ISI | ChemPort |
- Emini, E.A. et al. HIV and multidrug resistance. Nature 364, 679 (1993). | Article | PubMed | ISI | ChemPort |
- Larder, B.A., Kellam, P. & Kemp, S.D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365, 451−453 (1993). | Article | PubMed | ISI | ChemPort |
- Mellors, J.W. Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 175 (1996).
- Hammer, S.M., Katzenstein, D.A., Hughes, M.D., Hirsch, M.S. & Merigan, T.C. Abstracts 3rd Conf. Retroviruses and Opportunistic Infections, Washington, DC, 175 (1996).
- Cameron, B. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.162 (1996).
- Freimuth, W.W. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.162 (1996).
- Gulick, R. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.162 (1996).
- Mathez, D. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 106 (1996).
- Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483−489 (1995). | PubMed | ISI | ChemPort |
- Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117−122 (1995). | Article | PubMed | ISI | ChemPort |
- Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123−126 (1995). | Article | PubMed | ISI | ChemPort |
- Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.174 (1996).
- Mellors, J. et al. Abstracts 35th Intersci. Conf. on Antimicrobial Agents and Chemotherapy, San Francisco, California, 235 (1995).
- Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569−571 (1995). | Article | PubMed | ISI | ChemPort |
- Steigbigel, R.T. et al Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.80 (1996).
- Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528−1533 (1995). | Article | PubMed | ISI | ChemPort |
- Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534−1539 (1995). | Article | PubMed | ISI | ChemPort |
- Schapiro, J.M., Winters, M.A., Kozal, M.J. & Merigan, T.C. Abstracts 35th Intersci. Conf. Antimicrobial Agents and Chemotherapy, San Francisco, California, p.S8 (1995).
|
